Drug Development

Clinical Trials Antiviral Drugs GLP-1 Agonists Laboratory Infrastructure Immunotherapies AI in Healthcare Peptide Therapies NaV1.8 Inhibitors Non-Hormonal Contraceptives Natural Products

3 ARTICLES

last mo.

Researchers Unveil Efflux Resistance Breaker to Protect Antibiotics from Bacterial Pumps

Preclinical results published in the Journal of Medicinal Chemistry show modified fluoroquinolones restore activity in lab and mouse models and the team plans to move the approach toward commercialization and clinical testing.

10 ARTICLES

4mo ago

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

3 ARTICLES

4mo ago

New Single-Particle Assay Finds Disordered Lipid Nanoparticles Release RNA More Effectively

5 ARTICLES

5mo ago

Broad Flu Antibody Nasal Spray Shows Safety and Strong Nasal Neutralization in Phase 1

5 ARTICLES

5mo ago

Bristol Myers, Janux Strike Exclusive Deal on Tumor-Activated T-Cell Engager

8 ARTICLES

7mo ago

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

11 ARTICLES

8mo ago

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

6 ARTICLES

8mo ago

Biovac Opens Cape Town Product Development Lab to Advance Africa’s Vaccine Capacity

8 ARTICLES

8mo ago

Llama and Alpaca Nanobody Antivenom Neutralizes 17 African Elapid Venoms in Mice

5 ARTICLES

9mo ago

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

7 ARTICLES

10mo ago

CUNY Study Unveils Sugar-Targeting Compounds With Broad Antiviral Activity

3 ARTICLES

11mo ago

Mix-and-Go Cubosome Method Achieves Over 98% mRNA Encapsulation and Advances Toward Clinical Scale-Up

4 ARTICLES

11mo ago

Compound 3b Restores Meropenem's Potency Against WHO-Priority Klebsiella pneumoniae

4 ARTICLES

11mo ago

Roche’s New Antibiotic Against Acinetobacter baumannii Advances to Phase III Trials

5 ARTICLES

last yr.

Samsung Biologics Announces Spin-Off of Biosimilar Unit to Form Samsung Epis Holdings

3 ARTICLES

last yr.

Human-Derived Antibodies Drive Progress Toward Universal Snakebite Antivenom

Drug Development

Researchers Unveil Efflux Resistance Breaker to Protect Antibiotics from Bacterial Pumps

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

New Single-Particle Assay Finds Disordered Lipid Nanoparticles Release RNA More Effectively

Broad Flu Antibody Nasal Spray Shows Safety and Strong Nasal Neutralization in Phase 1

Bristol Myers, Janux Strike Exclusive Deal on Tumor-Activated T-Cell Engager

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Biovac Opens Cape Town Product Development Lab to Advance Africa’s Vaccine Capacity

Llama and Alpaca Nanobody Antivenom Neutralizes 17 African Elapid Venoms in Mice

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

Never miss stories about

Drug Development

CUNY Study Unveils Sugar-Targeting Compounds With Broad Antiviral Activity

Mix-and-Go Cubosome Method Achieves Over 98% mRNA Encapsulation and Advances Toward Clinical Scale-Up

Compound 3b Restores Meropenem's Potency Against WHO-Priority Klebsiella pneumoniae

Astrocyte-Derived Peptide Achieves Nausea-Free Weight Loss in Animal Models

Non-Hormonal Male Contraceptive Pill Passes Initial Safety Trial

YCT-529 Advances to Extended Human Trials After Clearing Initial Safety Test

Researchers Transform Ancient Tomb Fungus Into Potent Antileukemia Compound

Roche’s New Antibiotic Against Acinetobacter baumannii Advances to Phase III Trials

Samsung Biologics Announces Spin-Off of Biosimilar Unit to Form Samsung Epis Holdings

Human-Derived Antibodies Drive Progress Toward Universal Snakebite Antivenom

Never miss stories about

Drug Development